# Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

> **NCT04881929** · PHASE2 · UNKNOWN · sponsor: **Jiangsu Alphamab Biopharmaceuticals Co., Ltd** · enrollment: 30 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** KN026

## Key facts

- **NCT ID:** NCT04881929
- **Lead sponsor:** Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-09
- **Primary completion:** 2022-11-15
- **Final completion:** 2023-02-15
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2022-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04881929

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04881929, "Study of KN026 in Combination With Docetaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04881929. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*